Nature Reviews Drug Discovery

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2471
Vaccine exposes tumours to immune cell attack	1410
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	820
A specific biomarker for insoluble tau	624
Targeting tumour-associated bacteria	600
A new path to targeted protein degradation?	596
Neutralizing Zika virus	579
The improving benefit–risk balance of phase I cancer trials	555
FDA approves a c-MET-targeted ADC for lung cancer	536
Tumour cells get a dendritic cell makeover	505
Glucose-sensitive insulin protects against hypoglycaemia	485
Promoting tissue repair after heart attack	419
mRNA-encoded monoclonal antibody fights CHIKV	389
Hypoimmune iPSCs escape immune detection	383
Lipid nanoparticle ferries therapeutic mRNA to the placenta	382
FDA new drug approvals in Q1 2023	358
Apolipoprotein L2 inhibitor mitigates fibrosis	334
Degrading cell-free DNA to prevent recurrent stroke	333
FDA approves second TTR stabilizer for cardiac amyloidosis	325
Evolution of innovative drug R&D in China	322
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	322
2022 FDA approvals	305
Anti-tau antibody stumbles in phase II Alzheimer trial	303
New antibiotic for urinary tract infections nabs FDA approval	300
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	286

Targeting drug-resistant glioblastoma	280
Small-molecule discovery through DNA-encoded libraries	280
Chemical engineering of CRISPR–Cas systems for therapeutic application	277
Targeting the Hippo pathway in cancer	275
Top companies and drugs by sales in 2021	267
mRNA vaccines for infectious diseases — advances, challenges and opportunities	252
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	243
Increasing the potency of T cell therapies	229
Small molecule improves muscle function in myasthenia gravis	227
Blocking breast cancer metastasis	221
Pushing both sides of the drug pricing aisle	218
Host-directed antiviral blocks SARS-CoV-2 entry	217
TCR-engineered T cells get personal	203
FDA new drug approvals in Q2 2023	191
Inhibiting ASGR1 boosts cholesterol removal	187
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	182
Rewired proteostasis in KRAS inhibitor resistance	178
R&D re-balancing act	174
Screening ultra-large virtual libraries	171
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	170
A call to action for translational sciences in COVID-19 and future pandemics	167
Mimicking the health benefits of exercise	163
Reflections on 10 years of the FDA’s breakthrough therapy designation	162
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	158
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	157
The significance of blockbusters in the pharmaceutical industry	153
FDA approves second BCMA-targeted CAR-T cell therapy	152
Base editors hit the clinic	150
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	147
Amylin takes another shot at the obesity prize	135
Pan-coronavirus vaccine pipeline takes form	127
The emerging role of mass spectrometry-based proteomics in drug discovery	122
The antibody–drug conjugate landscape	118
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	118
Phenotypic drug discovery: recent successes, lessons learned and new directions	113
Antibody–drug conjugates come of age in oncology	113
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	111
Combating antimicrobial resistance in malaria, HIV and tuberculosis	110
Immunology on the brain	107
Multi-TACs target solid tumours	107
Gut metabolite mediates nerve repair	106
Reducing IL-2 toxicity	104
Agonist antibody lowers blood pressure	100
Monkeypox mRNA vaccine protects mice and macaques	98
Neglected tropical diseases go global	97
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	95
The malignant melanoma market	95
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	93
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	93
Anti-IL-11 antibody shows anti-ageing properties	92

GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	90
Ribosome inhibitor combats bacterial drug resistance	88
Designing G-protein-selective allosteric modulators	86
The European Innovation Network as a hub for medicines innovation in Europe	85
Targeting the ECM in melanoma	84
LRRK2-targeted Parkinson disease drug advances into phase III	82
Avidity in antibody effector functions and biotherapeutic drug design	81
Frameworks for transformational breakthroughs in RNA-based medicines	81
Engineered parasite delivers proteins to the brain	80
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	80
Engineering a compact genome-editing tool	79
Delivering genome editing tools to primary cells	78
RNA structure guides antiviral ASO design	74
Upcoming market catalysts in Q4 2023	73
A rush of CRISPR to the lungs	69
Covalent inhibitor engages oncogenic AKT kinase	69
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	68
Publisher Correction: Roflumilast	67
Broader horizons for cereblon glue degraders	63
Investigating the origins of recent pharmaceutical innovation	62
The non-small-cell lung cancer drug market	56
FDA approves first PSMA-targeted radiopharmaceutical	55
Accelerating precision oncology by converging pragmatic trials and real-world evidence	54
Betting on β-catenin inhibitors in oncology	53
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	50
MYC in cancer: from undruggable target to clinical trials	49
Targeting protein disorder: the next hurdle in drug discovery	49
Trends in the development of cellular and gene therapy in China	48
Promoting efferocytosis heals diabetic wounds	48
Identification of neoantigens for individualized therapeutic cancer vaccines	47
AAV-based in vivo gene therapy for neurological disorders	47
A bacteria-derived oral tumour vaccine	45
Three-step cures for autoimmune diseases?	45
V-ATPase inhibitor targets Ras-mutant cancers	44
Upcoming market catalysts in Q4 2024	42
Can large, simple trials bring drug developers back to common diseases?	41
Designing novel macrocyclic drugs	41
Microbial ‘dark matter’ yields new antibiotic	41
Towards a broad-spectrum antiviral agent	41
De novo design of macrocycles	40
FDA approves cell-sheet-based gene therapy for severe skin disease	40
Understanding LAG3 immune checkpoint function	40
Hinge modifier approach opens door to drugging HECT E3 ligases	39
A new drug target for NRAS(Q61) mutant-expressing cancers	38
2023 FDA approvals: unprecedented volume at moderate value	37
Glue-based KRAS inhibitors make their debut cancer trial mark	36
The evolution of the obesity drug market	35
PPAR agonists provide new treatment options for inflammatory liver disease	34
Neurotensin receptor modulator safely tackles pain	33
Calico, Alphabet’s anti-ageing play, goes it alone	33
Novel strategies to manage CAR-T cell toxicity	33
Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out	33
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	32
Cartilage regeneration for osteoarthritis	32
Analysis of China-to-West pharmaceutical licensing deals in 2024	32
The case for cell-penetrating peptides	31
RNA chemistry and therapeutics	31
RNA delivery heats up cold tumours	31
Therapeutically harnessing extracellular vesicles	30
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	30
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	29
Synthetic cytokine circuit targets solid tumours	28
A faster route to antidepressant activity	28
Refining HIV pre-exposure prophylactic agents	28
Transcription reprogramming to enhance CAR-T cell function	27
Targeting sigma receptor 1 in long QT syndrome	27
Designing closure-stabilizing integrin inhibitors	27
Designing a novel synthetic receptor	26
A step closer to in vivo editing of haematopoietic stem cells	26
Enhancing CAR-T cell efficacy through IFN ablation	25
FDA approves first factor XIIa inhibitor, for hereditary angioedema	25
Novel schizophrenia therapy filed for FDA approval	25
PD1 × VEGF blocking bispecifics for cancer draw big backing	24
FDA approves 21-valent pneumococcal vaccine	24
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	23
Improving efficacy of ASO therapy in SMA	23
CAR T cells take to the airways	22
FDA approves PI3Kα inhibitor that does double duty as a degrader	22
Unmet needs in vaccine development	22
Top product forecasts for 2025	21

Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	21
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	20
In vivo CAR T cells move into clinical trials	20
Genome-editing medicinal products: the EMA perspective	20
Designing insulin receptor agonists	20
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	20
RNAi-based drug design: considerations and future directions	20
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	19
Drugging the efferocytosis process: concepts and opportunities	19
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	19
Sequential immunotherapy: towards cures for autoimmunity	19
Targeting galectin-driven regulatory circuits in cancer and fibrosis	19
Understanding the effects of antibiotic combinations	18
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	18
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	18
Synthesizing portimines	18
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	18
Acyl-lysine reader inhibitor blocks AML progression	18
Brain glucose mediates amphotericin B tolerance	17
Treating cannabis use disorder	17
Epigenetic editor silences prion protein	17
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	17
Open-science drug discovery for COVID-19	17
Neurons give metastatic cells a push	17
Stalled molecular motor inhibits tumour growth	17
Bacteria tag tumours for CAR-T cell attack	17
Trustworthy AI for safe medicines	16
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	16
CRISPR activation tackles neurodevelopmental disorders	16
ASO targets DNA repair protein to combat Huntington disease	16
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	16
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	16
Building on the momentum of N-of-1 base editor therapies for rare diseases	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	16
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	15
Insights into new approach methodology innovation: an EMA perspective	15
opnMe.com: a digital initiative for sharing tools with the biomedical research community	15
The KRAS crowd targets its next cancer mutations	15
Bispecific antibodies in oncology	14
Alnylam scores big pharma support for angiotensinogen silencer	14
Thinking outside the box: non-canonical targets in multiple sclerosis	14
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	14
Trends in the drug target landscape for autoimmune diseases	14
Advanced technologies for the development of infectious disease vaccines	14
A new antibiotic for A. baumannii	13
Gene editing addresses antithrombin deficiency	13
Understanding sphingosine-1-phosphate transport	13
FDA releases tissue-agnostic cancer drug draft guidance	13
Antibody cocktail eliminates ebolaviruses	12
Setting GPCRs free	12
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	12
Understanding immunomodulatory antibody agonism	12
Upcoming market catalysts in Q3 2023	12
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	12
Soluble Notch agonists drive T cell production	12
The renal cell carcinoma drug market	12
Ramping up mitochondrial DNA replication	12
Hooking FSH as a potential target for Alzheimer disease	12
FDA approves first chikungunya vaccine	11
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	11
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	11
Phosphatase inhibitor drives anticancer immune responses	11
Targeting cytokine networks in neuroinflammatory diseases	11
Targeting ALDH1B1 in colorectal cancer	11
DUBTACs for targeted protein stabilization	10
FDA approves first two drugs for rare Niemann–Pick disease	10
Targeting ephrin signalling in sepsis	10
Inhibiting metallo-β-lactamases	10
Membrane transporters in drug development and as determinants of precision medicine	10
Targeting expanded trinucleotide repeats	10
Mapping cysteine ligandability	10
Macrophages as tools and targets in cancer therapy	10
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	10
Two-pronged approach for macular degeneration	10
New route to target RAS	10
Chromatin-targeted drug discovery at “a very special moment”	9
BacPROTAC to treat tuberculosis	9
Advances in the treatment of systemic lupus erythematosus	9
Repurposing beta-blockers in breast cancer	9
The potential of innovative trial design for efficiently evaluating repurposed drugs	9
Developing an IKZF2 glue degrader	9
Antibody drug conjugate combats inflammation	9
New therapeutic candidate for Chagas disease	9
2022 FDA approval number dips: a COVID-19 hangover?	9
Top product forecasts for 2026	8
Understanding semaglutide action in the brain	8
Novel drug targets in 2021	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
FDA approves PI3K inhibitor for a rare immune disorder	8
Roche buys MASH contender for up to US$3.5 billion	8
FDA approves BTK inhibitor for chronic hives	8
RNF41 reverses liver fibrosis	8
Opportunities for mitochondrial disease gene therapy	8
Fibrosis: cross-organ biology and pathways to development of innovative drugs	8